Alzheimer’s Disease Market

What is the Global Alzheimer’s Disease Market Size?

The Alzheimer’s disease market is estimated to grow from USD 11.3 billion in 2024 to reach USD 12.4 billion in 2025 and USD 29.4 billion by 2035, representing a higher CAGR of 9% during the forecast period.

To learn more about this report, request a free sample copy

Alzheimer's disease is a neurological condition characterized by the shrinkage of brain cells, leading to cognitive dysfunction, memory loss and dementia. This disease progresses with time and causes significant loss of social as well as behavioral ability of a person to perform day-to-day functions independently. In recent years, healthcare experts have noticed a rapid increase in the cases of neurological conditions, particularly Alzheimer's disease, worldwide.

As per the data provided by the Alzheimer's Association, over 7 million Americans are currently suffering from Alzheimer's disease. Further, the cases are likely to reach nearly 13 million by 2050. Given the growing concern about neurological disease, various pharmaceutical players are on the lookout for effective tests for diagnosis at early stages, and treatment options that can slow down the disease progression.

Investment from both public and private sectors is driving research and development in the Alzheimer's diseases domain, hence fostering innovation and aiding the introduction of cutting-edge therapies. Further, with growing emphasis on efficient treatment and diagnosis of these diseases, the market is poised for robust growth, offering significant opportunities for stakeholders in the coming years.

Alzheimer’s Disease Market: Report Attributes

The Alzheimer’s disease market analysis also features the likely distribution of the current and forecasted opportunity within the Alzheimer’s disease domain across various segments, such as type of treatment, symptomatic indications and geographical regions.

We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios represent different tracks of the industry's evolution.

Several promising advancements, such as, early detection of disease by specific biomarkers and novel imaging techniques are being implemented in this industry for effective treatment of Alzheimer’s disease. Additionally, the use of machine learning and big data in health care has significantly helped the drug developers and researchers for more accurate diagnosis, personalized treatment strategies and accelerated drug discovery.

What are the Recent Developments in the Alzheimer’s Disease Market ?

Several recent developments in the field of Alzheimer’s disease have occurred, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall Alzheimer’s disease market trends detailed in our analysis.

• In March 2026, Cognito Therapeutics secured $105 million in Series C funding round in order to support pivotal data readout, FDA submission, and commercial launch of its Spectris neuromodulation device for the treatment of Alzheimer's disease.
• In March 2026, the Alzheimer's Drug Discovery Foundation kicked off a $50 million phase of its $150 million Diagnostics Accelerator, supporting blood tests for tau and co-pathologies, multi-marker panels, and AI-powered biomarkers to speed up Alzheimer's drug development and support combination therapies.
• In March 2026, Eisai shared the latest long term real world data on lecanemab treatment from the four-year ahead 3-45 study, a public-private partnership with Biogen and the Alzheimer's Clinical Trial Consortium at 2026 conference focused on early Alzheimer's patients.
• In June 2025, Cure Parkinson’s entered into a collaboration with Alzheimer’s Research UK to share research findings, expertise, and resources, accelerating drug development for both Parkinson’s and Alzheimer’s diseases through collaborative efforts.

Alzheimer’s Disease Market Segmentation Insights

The market research report presents an in-depth analysis of the various Alzheimer’s disease drug developers, across different segments, as defined in the table below:

Alzheimer’s Disease Market: Market Segmentations

As the global incidence of Alzheimer’s disease increases, the demand for novel modalities and therapeutic agents for the treatment will increase as well, presenting lucrative opportunities for the stakeholders engaged in this domain.

Industry Experts on Alzheimer’s Disease Market

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

• President and Chief Executive Officer, Small Company, US
• Chief Executive Officer, Small Company, US
• Chief Executive Officer, Chairman and Founder, Small Company, US

Alzheimer’s disease domain will mark a turning point in 2025. Chris Viehbacher, (CEO, Biogen), stated that “We are doubling down in Alzheimer's”. This is because the company is expecting USFDA filing for subcutaneous Leqembi, which can be used as maintenance therapy.

How is the Alzheimer’s Disease Market Segmented?

Market Share by Type of Treatment: Disease Modifying Treatment Holds the Largest Share

• This segment highlights the distribution of market across various types of treatment, including symptomatic treatment and disease modifying treatment. According to our projections, the disease modifying treatment segment currently captures the highest Alzheimer’s disease market share (~55%) of the overall market in 2025. Further, this trend is unlikely to change in the near future, with the disease modifying treatment segment growing at a higher CAGR of 21% during the forecast period.
• The highest share is due to the fact that disease modifying treatment aims to target underlying pathology of the disease and slow down the disease progression rather than just managing the symptoms. They also assist in improving the long-term outcomes associated with therapy.

Market Share by Symptomatic Indication: Dementia Holds the Largest Share

• According to the Alzheimer’s disease market forecast the market is distributed across various symptomatic indications, including dementia, insomnia, and other physiological symptoms. According to our projections, in 2025, dementia accounts for the highest market share (~50%). This is likely to be a result of growing number of therapeutic drugs to treat cognitive symptoms such as dementia.
• The segment for insomnia is likely to be the fastest growing segment, with a CAGR of ~10% during the forecast period. This is because patients suffering from Alzheimer’s disease have a strong link between the disease progression and sleep disturbances, including conditions like sleep apnea. The increase in therapeutic agents for insomnia is also likely to increase the quality of life of patients.

Alzheimer’s Disease Treatment Market Size by Region 2025: North America Holds the Largest Share

• This segment highlights the distribution of market across various geographies, such as North America, Europe, Asia-Pacific and rest of the world. According to our projections, North America is likely to capture the majority of the Alzheimer’s disease market in 2025. This is due to a well-established healthcare infrastructure and robust government support to develop drugs for Alzheimer’s.
• It is worth highlighting that the market in Europe is likely to grow at a relatively higher CAGR (~15%), during the forecast period. This potential growth is due to the aging population, increased awareness and diagnosis, and advancements in treatment options.

Alzheimer’s Disease Market: Report Deliverables

What are the Major Takeaways of Alzheimer’s Disease Market?

The “Alzheimer’s Disease Market (2nd Edition): Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, publication analysis, partnerships and collaborations, funding and investments analysis, grant analysis, clinical trial analysis, patent analysis and market size and future opportunities within the Alzheimer’s disease industry, during the forecast period.

How is the Competitive Landscape of Alzheimer’s Disease Drug Developers Fragmented?

The current market landscape features close to 160 drug developers including very large, large, mid-sized and small companies. These players are currently taking various initiatives for the development of advanced therapeutic drugs to treat Alzheimer's disease.

It is worth noting here that currently more than 240 drug therapies are being evaluated either as a monotherapy or combination therapy across different stages of development. Notably, majority of these drugs are designed for oral administration.

What is the Opportunity for the Alzheimer’s Disease Market?

The global Alzheimer’s disease market size is likely to be worth $ 12.4 billion in 2025 and will reach $ 29.4 billion by 2035. In terms of the type of treatment type, disease modifying treatment segment holds the largest share of the market due to its ability to target underlying conditions. Further, the trend is unlikely to change in the foreseen future, with disease modifying treatment segment growing at a CAGR of ~21%.

The increasing prevalence of Alzheimer’s disease around the world, along with the rapid growth in research and development of novel disease modifying therapies is driving the growth of this market.

Which Region Holds the Largest Share of the Alzheimer’s Disease Market?

North America will Continue to Hold the Largest Share in the Market

North American companies are likely to dominate the global Alzheimer’s disease market in 2025, and the trend is unlikely to change in the near future with the market growing at a CAGR of ~10% during the forecast period. This is likely to be because of the high prevalence of disease, and robust research and development landscape in North America.

Europe: An Emerging Growth Spot

Due to the increased awareness and diagnosis of Alzheimer’s Disease in Europe, along with several advancements in treatment options, the market in Europe is likely to grow at a relatively high CAGR (~15%), during the forecast period till 2035.

What are the Key Challenges of Alzheimer’s Disease Market?

The high development cost associated with the research of therapeutic drugs is a tedious and time-consuming process. Furthermore, there is a high risk of failure associated with the drugs developed for this disease, which deter the investment and slow down the development process.

It is worth noting here that Alzheimer's is a progressive disease and has heterogeneous conditions with different subtypes. Thus, it is difficult to understand the underlying mechanism of disease and develop an effective treatment for targeting the disease. This creates a challenge for the key industrial leaders engaged in this domain.

Key Market Trends in Alzheimer’s Disease Market

Will Rising Partnerships and Collaborations Foster Progress and Innovation?

Alzheimer’s Disease drug developers have forged several partnerships with other stakeholders to enhance their current drug portfolios. Notably, maximum partnership instances in this domain are intercontinental deals, with North America accounting for close to 60% of the total partnerships. In the coming years, players engaged in this domain are likely to forge more such deals.

Growing number of Investments in the Global Alzheimer’s Disease Market

Over the years, monetary assistance from angel investors, venture capitalists, and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed start-ups / small companies to progress their research and development efforts in the global Alzheimer’s disease industry. Notably, the drug developers engaged in this domain have raised significant capital worth $ 4 billion in this domain.

From the Author’s Desk

Author’s View on Alzheimer’s Disease Market

The increasing prevalence of older population suffering from Alzheimer’s disease and the growing desire for novel therapeutics which can be used to manage the disease effectively, is facilitating the healthy growth of the market. However, challenges such as high development cost and disease complexity are hindering market growth.

About Author’s

Lead Author: Dakshita Dhawan

Lead Reviewer: Hardik Patel

Chief Editor: Prachi Bhalla

Glossary

• Amyloid Beta: It is a type of protein fragment which accumulates in the brain of Alzheimer’s patients and forms plaque.
• APOE (Apolipoprotein E): A gene associated with the increased risk of developing Alzheimer’s disease.
• Tau Protein: It is a protein which undergoes abnormal changes and detaches from the microtubules and clump together in the brain of patient’s suffering from Alzheimer’s disease.
• Dementia: This is a medical term describing a decline in memory, thinking, behavior and mental abilities.
• Paranoia: It is a persistent feeling of distrust and suspicion towards others.